Seven pharmaceutical companies were selected in 2017 list of brand value of Shanghai and Shenzhen listed companies

[China Pharmaceutical network industry trends] recently, the China trademark brand Research Institute of Renmin University of China released the 2017 list of brand value of Shanghai and Shenzhen listed companies Seven companies in the pharmaceutical industry were selected, including Shanghai pharmaceutical, Hengrui pharmaceutical, Yunnan Baiyao, East China pharmaceutical, Kangmei pharmaceutical, dong'a gum and Fosun pharmaceutical It is reported that the list is based on the brand value of listed companies Brand value of Shanghai Pharmaceutical: 22.86 billion yuan The main business of Shanghai Pharmaceutical covers the whole industrial chain of pharmaceutical R & D and manufacturing, distribution and retail It is the leading enterprise in the development of biomedical industry in Shanghai In the first half of 2018, Shanghai Pharmaceutical's operating revenue was 75.9 billion yuan, a year-on-year increase of 15.35%; the net profit attributable to shareholders of listed companies was 2.03 billion yuan, a year-on-year increase of 5.62% Brand value of Hengrui pharmaceutical: 20.859 billion yuan, Hengrui pharmaceutical is a pharmaceutical and health enterprise engaged in pharmaceutical innovation and high-quality R & D, production and promotion of essential products, as well as a domestic supplier of anti-tumor drugs, surgical drugs and contrast agents In the first three quarters of 2018, the operating revenue was 12.459 billion yuan, up 23.77% year on year; the net profit was 2.912 billion yuan, up 25.10% year on year The earnings per share is 0.79 yuan Brand value of Yunnan Baiyao: 19.907 billion yuan After years of development, Yunnan Baiyao's business involves the development, production and sales of chemical raw materials, chemical preparations, Chinese patent medicines, Chinese herbal medicines, biological products, health food, cosmetics and beverages In the first half of this year, Yunnan Baiyao's operating revenue was 12.974 billion yuan; the net profit attributable to the listed shareholders was 1.633 billion yuan; the company's total assets were 29.592 billion yuan; and the company's net assets were 19.671 billion yuan Brand value of Huadong pharmaceutical: 18.786 billion yuan, Huadong pharmaceutical is committed to the development, production and trade of drugs, and constantly promotes drugs with significant efficacy and advanced dosage forms The operating revenue of Huadong pharmaceutical in the first three quarters was 23204473939.34 yuan, a year-on-year increase of 8.17%, and the net profit attributable to shareholders of the listed company was 1809081209.36 yuan, a year-on-year increase of 21.48% The brand value of Kangmei pharmaceutical: 18.362 billion yuan, Kangmei pharmaceutical has two modern production bases, i.e Chinese herbal pieces and chemicals The business field involves in the operation of four categories of products and the distribution of terminal network In the first half of 2018, the operating income of comer Pharmaceutical Co., Ltd was RMB 16 billion 959 million; the net profit attributable to the listed shareholders was RMB 2 billion 605 million; the total assets of the company were RMB 78 billion 738 million; and the net assets of the company were RMB 33 billion 336 million Brand value of dong'a-jiao brand: 11.972 billion yuan dong'a-jiao brand belongs to dong'a-jiao Co., Ltd and dong'a-jiao Co., Ltd belongs to central enterprise China Resources Group It has been shortlisted in China's top 500 value brands for many times, and its brand value has been improved for many times In the first half of the year, the operating revenue of dong'a-jiao was 2.986 billion yuan; the net profit attributable to the listed shareholders was 862 million yuan; the company's total assets were 12.396 billion yuan; and the company's net assets were 10.121 billion yuan Brand value of Fosun Pharmaceutical: 11.565 billion yuan, Fosun Pharmaceutical focuses on the modern biomedical health industry, seizing the rapid growth of China's pharmaceutical market and the huge opportunity for Chinese enterprises to enter the world's mainstream pharmaceutical market, forming a large-scale professional pharmaceutical health industry group with drug R & D and manufacturing as the core In the first half of 2018, Fosun Pharmaceutical's operating revenue was 11.859 billion yuan, up 41.97% year-on-year; R & D investment was 1.188 billion yuan, up 89.82% year-on-year.